Patents Examined by Oluwatosin Ogunbiyi
  • Patent number: 11504433
    Abstract: The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: November 22, 2022
    Assignee: Applied Molecular Transport Inc.
    Inventors: Thomas Carl Hunter, Randall J. Mrsny, Weijun Feng, Tahir Mahmood, Charles Olson, Sally Postlethwaite
  • Patent number: 11498958
    Abstract: Described herein are methods of treating, diagnosing, and/or prognosing a disease in a subject relating to detection of the glycosylation state of the antibodies present in the subject. In some embodiments, the disease can be an infection. In some embodiments, an antibody glycosylation state that is indicative of the presence of a disease, or a need for treatment of a disease can be reduced glycosylation (e.g., galactosylation, sialation, fucosylation, and/or afucosylated branched glycoforms).
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: November 15, 2022
    Assignees: THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Galit Alter, Sarah Fortune, Amy Chung
  • Patent number: 11497804
    Abstract: The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pilin-like protein ComP using a Pg1LComP O-OTase. Uses of glycoproteins synthesized by glycosylating ComP using Pg1LComP O-OTase, particularly for the preparation of vaccines and the like, including a vaccine to Streptococcus, is also provided.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: November 15, 2022
    Assignee: VaxNewMo LLC
    Inventors: Mario Feldman, Mohamed Adel Nasr
  • Patent number: 11491215
    Abstract: Provided herein are antigenic combinations and related compositions, methods and systems for immunizing a host from an infection caused by Francisella bacterium. The antigenic combination comprises an antigenic polysaccharide component from a Francisella bacterium capable of triggering a humoral immune response in an individual, a protein antigen component from the Francisella bacterium capable of triggering a cellular immune response in the individual, and an adjuvant, the antigenic Francisella polysaccharide component, the Francisella protein antigen component and the adjuvant are in a suitable amount to immunize an individual against the Francisella bacterium.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: November 8, 2022
    Assignees: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, REGENTS OF THE UNIVERSITY OF NEW MEXICO
    Inventors: Nicholas Fischer, Amy Rasley, Terry Wu, Julie Lovchik
  • Patent number: 11485976
    Abstract: This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: November 1, 2022
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTD
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 11484555
    Abstract: The present invention relates to a novel use of a bacterial secretome in the field of the treatment of skin lesions and more particularly of wound healing. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial secretome as active agent.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: November 1, 2022
    Assignee: PIERRE FABRE DERMO-COSMETIQUE
    Inventors: Nathalie Castex-Rizzi, Marie Florence Galliano, Hélène Hernandez-Pigeon
  • Patent number: 11484582
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: November 1, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
  • Patent number: 11484556
    Abstract: A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more Bacillus species, and heating to a preferred elevated temperature range of 41° C. to 44° C. for an incubation period of around 2 to 60 minutes. The nutrient-germinant composition is preferably in a concentrated liquid form that is diluted just prior to initiating the germination/incubation method at the point of use. The method may also include dispensing a germinated spore solution to a point-of-use/consumption, such as animal feed, water, or bedding, or a wastewater system or drain.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 1, 2022
    Assignee: NCH Corporation
    Inventors: Gabriel F. K. Everett, Charles Greenwald, Judy Pruitt, Amanda Rosmarin, Jordan Church, Daniel Aberle, George Aboagye
  • Patent number: 11471495
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 18, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney
  • Patent number: 11471496
    Abstract: The present invention provides compositions and methods for treating, ameliorating, and/or preventing cocaine addiction in a subject. Immunization by M. vaccae alters serotonin signaling in the brain, reducing stress- and anxiety-like responding in animal models of post-traumatic stress disorder and other anxiety disorders. In certain embodiments, the immunoregulatory, anti-stress, and anxiolytic effects of M. vaccae immunization reduces addiction- and relapse-like responding in models of cocaine addiction and alter the development of cocaine-induced neuroinflammation.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: October 18, 2022
    Assignees: Rowan University, The Regents of the University of Colorado
    Inventors: Thomas M. Keck, Christopher A. Lowry
  • Patent number: 11473091
    Abstract: The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1?; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: October 18, 2022
    Assignee: ILYA PHARMA AB
    Inventor: Evelina Vågesjö
  • Patent number: 11464844
    Abstract: Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: October 11, 2022
    Assignee: Boston Medical Center Corporation
    Inventor: Richard N. Goldstein
  • Patent number: 11459379
    Abstract: The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 4, 2022
    Assignee: Research Development Foundation
    Inventors: Jere W. McBride, Christopher K. Doyle
  • Patent number: 11453715
    Abstract: The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: September 27, 2022
    Assignee: NEW YORK UNIVERSITY
    Inventors: Victor J. Torres, Tamara Reyes-Robles, Francis Alonzo, III
  • Patent number: 11447560
    Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: September 20, 2022
    Assignees: KECK GRADUATE INSTITUTE, H. LUNDBECK A/S
    Inventors: James M. Cregg, John A. Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstrorukov
  • Patent number: 11433106
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: September 6, 2022
    Assignee: 4D Pharma Research Limited
    Inventors: George Grant, Angela Margaret Patterson, Imke Mulder, Seanin McCluskey, Emma Raftis
  • Patent number: 11426453
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: August 30, 2022
    Assignee: Vakzine Projekt Management GmbH
    Inventor: Leander Grode
  • Patent number: 11419902
    Abstract: The invention provides a composition comprising a bacterial strain of the genus Megasphaera, for use in stimulating the immune system in subject.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 23, 2022
    Assignee: 4D Pharma Research Limited
    Inventors: Imke Elisabeth Mulder, Parthena Fotiadou, Amy Beth Holt, Suaad Ahmed, Anna Ettorre, Samantha Yuille, Ted Dinan, John Cryan
  • Patent number: 11414668
    Abstract: The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1?; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: August 16, 2022
    Assignee: ILYA PHARMA AB
    Inventor: Evelina Vågesjö
  • Patent number: 11401308
    Abstract: There is provided novel peptides for use in diagnosis of CagA+ H. pylori infection or the prediction of risk for gastric cancer. The peptides bind antibodies from CagA+ H. pylori patients with high specificity and sensitivity, and can be used for example in a diagnostic kit.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: August 2, 2022
    Assignee: Biotome Pty Ltd.
    Inventor: Bror Samuel Lundin